Targets › ENPP1
5 programs from 5 companies in 9 trials: 4 Phase 1, 3 Phase 2, 1 Phase 4, 1 Phase 3; Oncology, Gastroenterology, Other; next expected readout Apr 2027.
Nucleotide pyrophosphatase that generates diphosphate (PPi) and functions in bone mineralization and soft tissue calcification by regulating pyrophosphate levels (By similarity). PPi inhibits bone mineralization and soft tissue calcification by binding to nascent hydroxyapatite crystals, thereby preventing further growth of these crystals. (UniProt, P22413)
Open in Phaseline: the race on ENPP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Colgate Palmolive | sodium monofluorophosphate toothpaste Fluoride source for dental remineralization and caries prevention | ENPP1 | Phase 4 | Gingivitis | – |
| Inozyme Pharma | INZ-701 Recombinant ENPP1-Fc fusion protein | ENPP1 | Phase 3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Gene Mutations; Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | – |
| Riboscience | RBS2418 Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) inhibitor that increases cGAMP | ENPP1 | Phase 2 | Advanced Unresectable Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Advanced Cancer | Apr 2027 |
| Arjun Deb, MD | AD-NP1 humanized monoclonal antibody targeting the catalytic domain of human ENPP1 | ENPP1 | Phase 1 | Maximum Tolerated Dose | Jan 2028 |
| Stingray Therapeutics | SR-8541A ENPP1 inhibitor | ENPP1 | Phase 1 | Advanced / Metastatic Solid Tumor | – |
Advanced Unresectable Hepatocellular Carcinoma (1) Metastatic Colorectal Cancer (1) Advanced Cancer (1) Gingivitis (1) Advanced / Metastatic Solid Tumor (1) Maximum Tolerated Dose (1) Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency (1) Gene Mutations (1) Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency (1)
small molecule (4), mixed (1)
Riboscience (1) Colgate Palmolive (1) Stingray Therapeutics (1) Arjun Deb, MD (1) Inozyme Pharma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.